-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Upgrades Genmab to Buy, Raises Price Target to $43

Benzinga·07/22/2026 17:28:53
语音播报
TD Cowen analyst Yaron Werber upgrades Genmab (NASDAQ:GMAB) from Hold to Buy and raises the price target from $32 to $43.